secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001104659-24-057228
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet Biosciences appoints Thierry Chauche as CFO, effective May 6, 2024
--------------------------------------------------------------------------

- Thierry Chauche named CFO, replacing interim CFO Joseph Oriti who resigned.
- Chauche receives $480k base salary, 40% target bonus, and option grant valued at $2M (Black-Scholes).
- Option vests over 4 years (25% cliff at 1 year, then monthly).
- Severance: 6 months base salary (12 months during change in control), plus COBRA and equity acceleration.
- Chauche previously CFO of Provention Bio and held roles at Alexion, Intercept, Novartis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/0001104659-24-057228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924057228/tm2413539d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-057228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer